Predictors of acute toxicities during definitive chemoradiation using intensity-modulated radiotherapy for anal squamous cell carcinoma

References

• Ajani JA, Winter KA, Gunderson LL, Pederson J, Benson AB 3rd, Thomas CR Jr, et al. Fluorouracil, mitomycin and radiotherapy vs. fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: A randomized controlled trial. JAMA 2008;299:1914–21.
   PubMed Web of Science ®Google Scholar
• Bazan JG, Luxton G, Mok EC, Koong AC, Chang DT. Normal tissue complication probability modeling of acute hematologic toxicity in patients treated with intensity modulated radiation therapy for squamous cell carcinoma of the anal canal. Int J Radiat Oncol Biol Phys 2012;84:700–6.
   PubMed Web of Science ®Google Scholar
• Salama JK, Mell LK, Schomas DA, Miller RC, Devisetty K, Jani AB, et al. Concurrent chemotherapy and intensity-modulated radiation therapy for anal cancer patients: A multicenter experience. J Clin Oncol 2007;25:4581–6.
   PubMed Web of Science ®Google Scholar
• Saarilahti K, Arponen P, Vaalavirta L, Tenhunen M. The effect of intensity-modulated radiotherapy and high dose rate brachytherapy on acute and late radiotherapy-related adverse events following chemoradiotherapy of anal cancer. Radiother Oncol 2008;87:383–90.
   PubMed Web of Science ®Google Scholar
• Kachnic LA, Winter K, Myerson RJ, Goodyear MD, Willins J, Esthappan J, et al. RTOG 0529: A phase II evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal. Int J Radiat Oncol Biol Phys 2013;86:27–33.
   PubMed Web of Science ®Google Scholar
• Kachnic LA, Tsai HK, Coen JJ, Blaszkowsky LS, Hartshorn K, Kwak EL, et al. Dose-painted intensity-modulated radiation therapy for anal cancer: A multi-institutional report of acute toxicity and response to therapy. Int J Radiat Oncol Biol Phys 2012;82:153–8.
   PubMed Web of Science ®Google Scholar
• Bazan JG, Luxton G, Kozak MM, Anderson EM, Hancock SL, Kapp DS, et al. Impact of chemotherapy on normal tissue complication probability models of acute hematologic toxicity in patients receiving pelvic intensity modulated radiation therapy. Int J Radiat Oncol Biol Phys 2013;87:983–91.
   PubMed Web of Science ®Google Scholar
• Myerson R, Garofalo M, El Naqa I, Abrams RA, Apte A, Bosch WR, et al. Elective clinical target volumes in anorectal cancer: An RTOG consensus panel contouring atlas. Int J Radiat Oncol Biol Phys 2009;74:824–30.
   PubMed Web of Science ®Google Scholar
• Dasgupta T, Rothenstein D, Chou J, Zhang Z, Wright JL, Saltz LB, et al. Intensity-modulated radiotherapy vs. conventional radiotherapy in the treatment of anal squamous cell carcinoma: A propensity score analysis. Radiother Oncol 2013;107:189–94.
   PubMed Web of Science ®Google Scholar
• Day FL, Link E, Ngan S, Leong T, Moodie K, Lynch C, et al. FDG-PET metabolic response predicts outcomes in anal cancer managed with chemoradiotherapy. Br J Cancer 2011;105:498–504.
   PubMed Web of Science ®Google Scholar
• Deasy JO, Blanco AI, Clark VH. CERR: A computational environment for radiotherapy research. Med Phys 2003;30:979–85.
   PubMed Web of Science ®Google Scholar
• El Naqa I, Suneja G, Lindsay PE, Hope AJ, Alaly JR, Vicic M, et al. Dose response explorer: An integrated open-source tool for exploring and modelling radiotherapy dose-volume outcome relationships. Phys Med Biol 2006;51:5719–35.
   PubMed Web of Science ®Google Scholar
• Milano MT, Jani AB, Farrey KJ, Rash C, Heimann R, Chmura SJ. Intensity-modulated radiation therapy (IMRT) in the treatment of anal cancer: Toxicity and clinical outcome. Int J Radiat Oncol Biol Phys 2005;63:354–61.
   PubMed Web of Science ®Google Scholar
• Mell LK, Schomas DA, Salama JK, Devisetty K, Aydogan B, Miller RC, et al. Assocation between bone marrow dosimetric parameters and acute hematologic toxicity in anal cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys 2008;70:1431–7.
   PubMed Web of Science ®Google Scholar
• James R, Wan S, Glynne-Jones R. A randomised trial of chemoradiation using mitomycin or cisplatin with or without maintenance cisplatin/5-FU in squamous cell carcinoma of the anus. ACT II. J Clin Oncol 2009;18S:27.
   Google Scholar
• Flam M, Madhu J, Pajak TF, Petrelli N, Myerson R, Doggett S, et al. Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: Results of a phase III randomized intergroup study. J Clin Oncol 1996;14:2527–39.
   PubMed Web of Science ®Google Scholar
• Cheng JC, Bazan JG, Wu JK, Koong AC, Chang DT. Lumbosacral spine and marrow cavity modeling of acute hematologic toxicity in patients treated with intensity modulated radiation therapy for squamous cell carcinoma of the anal canal. Pract Radiat Oncol 2014;4:198–206.
   PubMedGoogle Scholar
• Devisetty K, Mell LK, Salama JK, Schomas DA, Miller RC, Jani AB, et al. A multi-institutional acute gastrointestinal toxicity analysis of anal cancer patients treated with concurrent intensity-modulated radiation therapy (IMRT) and chemotherapy. Radiother Oncol 2009;93:298–301.
   PubMed Web of Science ®Google Scholar